The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | NETTER-2: 177Lu-DOTATATE in gastroenteropancreatic NETs
Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, gives an overview of the Phase II NETTER-2 trial (NCT03972488) of the radioligand 177Lu-DOTATATE in gastroenteropancreatic neuroendocrine tumors (NETs). Patients with grade 2 or 3 tumors, as well as tumors originating from the pancreas or small intestine were enrolled. 177Lu-DOTATATE in the first line setting was proven to be efficacious in all cohorts, suggesting that it should be the standard of care in this setting. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
